The CCNM™ protocol defines a targeted set of tests designed to detect the major disease categories responsible for most premature deaths cardiovascular, cancer, neurological, and metabolic conditions. Rather than performing random investigations, CCNM™ ensures screening is structured, evidence-aligned, and focused on high-impact diseases in early detection.

We do not rely on a single test or marker. By integrating imaging, blood biomarkers, genetics, and other biological data, we synthesize signals across systems, reducing false positives, minimizing false negatives, and improving overall detection clarity.

Our AI models enhance imaging scan quality and assists in identifying subtle structural changes that may be difficult to detect in early stages. Every AI output is validated by specialists, combining computational precision with medical expertise.